GlassScriptPhysician profile
Karanbir Brar
NPI 1306191473
$9,399.13
in general payments reported to CMS, 2019-2025
41 companies · $536 in 2025
The $536 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $219 · 2021: $2,479 · 2022: $1,091 · 2023: $4,295 · 2024: $656 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,150 · Food and Beverage: $2,212 · Travel and Lodging: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,150.00 |
| Food and Beverage | $2,212.09 |
| Travel and Lodging | $125.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,629.43 | 2021-2025 | Prolia, Evenity, Prolia |
| Abbvie INC. | $1,611.49 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,512.30 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $480.00 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $243.51 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $224.78 | 2021-2024 | Farxiga, Airsupra |
| Allergan, INC. | $171.89 | 2019-2020 | |
| Pfizer INC. | $133.90 | 2020-2024 | |
| Biogen, INC. | $131.50 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.53 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $119.65 | 2020-2023 | Xarelto |
| Boston Scientific Corporation | $118.54 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Merck Sharp & Dohme LLC | $93.19 | 2020-2024 | Dificid, Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $81.88 | 2022 | |
| Seqirus USA INC | $69.44 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karanbir Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.